[The position of drospirenone in premenstrual syndrome teratment].
OBJECTIVE
To evaluate influence of hormonal contraceptive drospirenone on premenstrual syndrome (PMS).


METHODS
Overall summary of literature. AUTHOR AFFILIATION: ADC Sanatorium, Praha.


METHODS
Review of scientific studies and publications.


CONCLUSIONS
The author submitted current opinions on premenstrual syndrome, its classification, and treatment. The role of renin--aldosterone system in the genesis of PMS was described. Basic pharmacological characteristics of the remedy containing in one pill 30 mg of Ethinyl Estradiol (EE) and 3 mg of drospirenone are presented. Its therapeutic effects on somatic and psychological PMS symptoms are discussed.
Havlín
M
M
ADC Sanatorium, Praha.
D000736:Androstenes / Q000627:therapeutic use*; D003270:Contraceptive Agents; D005260:Female; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D011293:Premenstrual Syndrome / Q000188:drug therapy*
D000736:Androstenes; D003270:Contraceptive Agents; D000451:Mineralocorticoid Receptor Antagonists; C035144:drospirenone